טוען...
Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
Poly(ADP-ribose)polymerase (PARP) inhibitors (PARPi) have recently been approved for the treatment of breast and ovarian tumors with defects in homologous recombination repair (HRR). Although it has been demonstrated that PARPi also sensitize HRR competent tumors to cytotoxic chemotherapies or radio...
שמור ב:
| הוצא לאור ב: | Molecules |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6514732/ https://ncbi.nlm.nih.gov/pubmed/31010230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/molecules24081559 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|